Orthocell (ASX:OCC) Insider Buys A$132,276.10 in Stock

Orthocell Limited (ASX:OCC) insider Paul Anderson bought 126,580 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The shares were purchased at an average price of A$1.05 per share, for a total transaction of A$132,276.10.

Orthocell Price Performance

The firm has a market cap of $375.52 million, a price-to-earnings ratio of -42.23 and a beta of 1.16. The company has a quick ratio of 5.07, a current ratio of 4.34 and a debt-to-equity ratio of 15.22.

Orthocell Company Profile

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; and Remplir, a collagen scaffold used in peripheral nerve repair.